Biohaven Returns To Well With Bristol License, Acquires Channel Biosciences

 
• By Joseph Haas

With Nurtec and zavegepant in hand from Bristol, Biohaven tries for another success with a spinal muscular atrophy asset. It will move into epilepsy indications with the buyout of Channel, a subsidiary of Knopp.

Two Cubs image Biohaven story
Biohaven's new deals add two up-and-coming assets to its pipeline • Source: Alamy

More from Strategy

More from Business